Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Agios Pharmaceuticals (AGIO) Shares Repurchased (2021)

Agios Pharmaceuticals (AGIO) has disclosed Shares Repurchased for 1 consecutive years, with $19.0 million as the latest value for Q4 2021.

For Q4 2021, Shares Repurchased changed N/A year-over-year to $19.0 million; the TTM value through Dec 2022 reached $273.4 million, changed 0.0%, while the annual FY2021 figure was $802.5 million, N/A changed from the prior year.
Shares Repurchased hit $19.0 million in Q4 2021 for Agios Pharmaceuticals, down from $254.4 million in the prior quarter.
Across five years, Shares Repurchased topped out at $254.4 million in Q3 2021 and bottomed at $19.0 million in Q4 2021.